• News
  • SAN DIEGO
  • BioTech

Cadence and Perrigo settle patent dispute

San Diego-based Cadence Pharmaceuticals Inc. (Nasdaq: CADX) said Wednesday that it settled a patent dispute with Perrigo Co. (Nasdaq: PRGO) on its only marketed drug, the fever and pain treatment Ofirmev.

Under the settlement Perrigo Co. can start selling a generic version of Ofirmev starting Dec. 6, 2020. That's six months before the last patents supporting the drug expire. If Cadence decides to launch an authorized generic version of the drug, Perrigo will have the right of first refusal to negotiate with Cadence about making that product.

Ofirmev is an injectable version of the drug acetaminophen. Perrigo said annual sales of the drug are about $42 million.

Shares of Cadence rose 47 cents, or 12 percent, to $4.40 in late afternoon trading Thursday. Perrigo is based in Allegan, Mich. Its shares were down 9 cents to $103.18.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.